Agreement gives ReachBio exclusive North American distribution rights to pure cardiomyocytes and other novel ES cell-derived products for drug
discovery, toxicity testing, and R&D applications
SEATTLE, Feb. 27 /PRNewswire/ -- ReachBio LLC (Seattle, WA) announced today that it will distribute the full product line of Axiogenesis AG (Cologne, Germany) to the North American life science research and drug discovery market.
Axiogenesis' products consist of highly pure and well-characterized tissue-specific cells derived from specially engineered mouse embryonic stem cell lines. Major applications for the cells include drug discovery, toxicity testing of new drug candidates and other compounds, and basic research. The first cell types available from Axiogenesis are 99.9% pure atrial cardiomyocytes in various formats, including frozen cryovials, pre-seeded 96-well plates, and pre-seeded coverslips. Branded as Cor.AT cells, these cardiomyocytes have been rigorously functionally qualified and found to be ideal for cardiotoxicity screening, electrophysiology studies, and as a cellular model system for hypertrophic cardiomyopathy. Pure ventricular cardiomyocytes (Cor.VE) are also available.
Commenting on the new relationship, Axiogenesis' CEO, Dr. Heribert
Bohlen said, "We are very happy that ReachBio will be representing our
products in North America. They share our philosophy that cellular model
systems for drug discovery and toxicity testing should utilize highly
relevant cells that are as close to the natural state as possible. The
biopharma industry is trying to find ways to move away from the use of
artificial cell lines that have questionable biological significance in the
drug development process, and towards more biologically relevant cellular
systems. ReachBio is at t
|SOURCE ReachBio LLC|
Copyright©2008 PR Newswire.
All rights reserved